(Q36802676)

16 August 2017

1 reference

title

Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug (English)

1 reference

16 August 2017

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494152&resulttype=core&format=json

14 May 2020

1

Tim De Smedt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494152&resulttype=core&format=json

14 May 2020

author name string

Robrecht Raedt

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494152&resulttype=core&format=json

14 May 2020

Kristl Vonck

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494152&resulttype=core&format=json

14 May 2020

language of work or name

1 reference

1 January 2007

1 reference

17461890

CNS Neuroscience & Therapeutics

16 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494152&resulttype=core&format=json

14 May 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494152&resulttype=core&format=json

14 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494152&resulttype=core&format=json

14 May 2020

page(s)

57-78

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494152&resulttype=core&format=json

Levetiracetam monotherapy for newly diagnosed epilepsy patients.

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Revisiting the concept of identifiable neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Levetiracetam monotherapy for primary generalised epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

The long term retention of levetiracetam in a large cohort of patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Clinical profile and course of cognitively normal patients evaluated in memory disorders clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Use of levetiracetam in special populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Levetiracetam in the treatment of idiopathic generalized epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Safety profile of levetiracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Optimizing therapy of seizures in women who use oral contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Levetiracetam concentrations in serum and in breast milk at birth and during lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Levetiracetam for people with mental retardation and refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Long-term continuation of levetiracetam in patients with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Levetiracetam monotherapy during pregnancy: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Assessment of a dose-response relationship of levetiracetam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Psychiatric adverse events during levetiracetam therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Clinical pharmacokinetics of levetiracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Pharmacokinetic study of levetiracetam in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

The management of refractory idiopathic epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Efficacy of levetiracetam: a review of three pivotal clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Effect of levetiracetam on human corticospinal excitability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Valproate irreversibly alters steroid secretion patterns from porcine follicular cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Valproate inhibits the conversion of testosterone to estradiol and acts as an apoptotic agent in growing porcine ovarian follicular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Comparison of reproductive effects of levetiracetam and valproate studied in prepubertal porcine ovarian follicular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Levetiracetam use and pregnancy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Discontinuation of levetiracetam because of behavioral side effects: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2007.00005.X

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

21 January 2018

1 reference

12 December 2020

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

1 reference

12 December 2020

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

1 reference

12 December 2020

Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy

1 reference

12 December 2020

The 'number needed to treat' with Levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs).

1 reference

12 December 2020

A systematic review of the safety profile of levetiracetam: a new antiepileptic drug.

1 reference

12 December 2020

Levetiracetam: a different approach to the pharmacotherapy of epilepsy

1 reference

12 December 2020

A new antiepileptic drug.

1 reference

12 December 2020

Preliminary efficacy of levetiracetam in monotherapy.

1 reference

12 December 2020

Safety profile of levetiracetam

1 reference

12 December 2020

Levetiracetam and partial seizure subtypes: pooled data from three randomized, placebo-controlled trials

1 reference

12 December 2020

Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study.

1 reference

12 December 2020

Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures

1 reference

12 December 2020

Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy

1 reference

12 December 2020

Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study

1 reference

12 December 2020

Levetiracetam: a long-term follow-up study of efficacy and safety

1 reference

12 December 2020

Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy.

1 reference

12 December 2020

Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register

1 reference

12 December 2020

Equipoise and the ethics of clinical research

1 reference

12 December 2020

Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam

1 reference

12 December 2020

10.1111/J.1527-3458.2007.00005.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494152&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494152&resulttype=core&format=json

14 May 2020

17461890

1 reference